Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of 6 months to 18 years of age~* Presenting for emergency treatment within 5 hours with clinically important systemic signs of scorpion sting envenomation.~* Signed written Informed Consent by patient or legal guardian.~* No participation in a clinical drug trial within the last month or concomitantly.~Exclusion Criteria:~* Allergy to horse serum.~* Use within the past 24 hours of drugs expected to alter immune response: H1 or H2 blockers, corticosteroids.~* Use of any antivenom within the last month or concomitantly.~* Underlying medical conditions that significantly alter immune response: bone marrow suppression congenital or acquired immuno-deficiency state, chemotherapy and chronic corticosteroid use.~* Allergy to midazolam.~* More than 0.3mg/kg of body weight of midazolam administered during the hour prior to study drug infusion.~* Concurrent medical condition involving a baseline neurologic status mimicking envenomation (chorea, tardive dyskinesia, uncontrolled epilepsy).~* Pregnant and nursing women.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Alacramyn and midazolam as needed
- 2 (Type: PLACEBO_COMPARATOR): placebo and midazolam as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).